Table 5. Summary of PK parameters (mean±s.d.) of HSP990 following the oral doses on day 1 of cycle 1.
| Dose | Cmax (ng ml−1) | Tmax (h) | AUCinf (ng.h ml−1) | AUClast (ng.h ml−1) | T1/2 (h) |
|---|---|---|---|---|---|
| 2.5 mg weekly (N=3) |
12.9±4.3 |
2.98–3.05 |
394±77 |
309±31 |
25.6±17.1 |
| 5 mg weekly (N=5) |
24.5±6.5 |
1.0–23.2 |
915±375 |
835±373 |
26.1±9.7 |
| 10 mg weekly (N=7) |
70.3±29.9 |
3.0–8.03 |
1993±1073 |
1883±1049 |
19.0±4.6 |
| 20 mg weekly (N=6) |
129±89 |
3.0–8.0 |
4027±2843 |
3667±2715 |
20.4±4.1 |
| 30 mg weekly (N=5) |
253±83 |
3.0–4.0 |
6142±2428 |
5854±2358 |
16.8±1.0 |
| 50 mg weekly (N=22) |
496±279 |
2.95–5.97 |
10 108±10229 |
8408±5569 |
20.2±10.9 |
| 60 mg weekly (N=5) |
700±424 |
3.0–3.08 |
9712±4901 |
9405±4939 |
17.6±4.9 |
| 25 mg twice weekly (N=11) | 270±125 | 1.0–75.8 | NA | 12 580±s | 17.9±9.4 |
Abbreviations: AUC=area under the curve; NA=not applicable; PK=pharmacokinetic.